FHCR-1-2813/FDC-6細(xì)胞
數(shù)量： 大量
運(yùn)輸方式： 凍存運(yùn)輸
細(xì)胞形態(tài)： **樣
**類型： IgG1
生長狀態(tài)： 懸浮生長
ATCC Number： HB-9018?
是否是腫瘤細(xì)胞： 0
物種來源： 小鼠
Designations: FHCR-1-2813/FDC-6
Depositors: Fred Hutchinson Cancer Res. Cntr.
Isotype: IgG1
Biosafety Level: 1
FHCR-1-2813/FDC-6細(xì)胞Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against an onco-fetal determinant on human fibronectin
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with fibronectin from HuH-6 human hepatoma cells.
Spleen cells were fused with SP-1 myeloma cells.
The antibody reacts with human fibronectin from fetal and neoplastic tissues, but not from normal human tissues or plasma.
Propagation: FHCR-1-2813/FDC-6細(xì)胞ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 88%; fetal bovine serum, 12%
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: FHCR-1-2813/FDC-6細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1801: Loridon-Rosa B, et al. Distribution of oncofetal fibronectin in human mammary tumors: Immunofluorescence study on histological sections. Cancer Res. 50: 1608-1612, 1990. PubMed: 2406016
1802: Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal ***** tissues and plasma. Proc. Natl. Acad. Sci. USA 82: 6517-6521, 1985. PubMed: 2995969
1803: Matsuura H, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J. Biol. Chem. 263: 3314-3322, 1988. PubMed: 2449438
4008: Matsuura H, Hakomori S. Monoclonal antibody defining oncofetal structure of fibronectin. US Patent 4,894,326 dated Jan 16 1990
23548: FHCR-1-2813/FDC-6細(xì)胞Matsuura H, et al. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J. Biol. Chem. 264: 10472-10476, 1989. PubMed: 2471705
